Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

He-Li Gao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110629717. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2018: 4 papers · 2019: 4 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. [Corrigendum] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2025.5822↗
  2. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. Co-author DOI 10.3748/wjg.v26.i8.828↗
  3. Angiogenesis in pancreatic cancer: current research status and clinical implications. Co-author DOI 10.1007/s10456-018-9645-2↗
  4. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2018.10.539↗
  5. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Co-author DOI 10.2174/0929867325666180413101722↗
  6. The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. Co-author DOI 10.7150/jca.30883↗
  7. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. Co-author DOI 10.1016/j.hbpd.2018.03.007↗
  8. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  9. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2018.4269↗
  10. The Significance of Liquid Biopsy in Pancreatic Cancer. Co-author DOI 10.7150/jca.24591↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaxiang Xu · 10 shared papers, 2018–2026 · strength 1.01
  2. Chuntao Wu · 10 shared papers, 2018–2026 · strength 1.01
  3. Xianjun Yu · 10 shared papers, 2018–2026 · strength 1.01
  4. Shi-Rong Zhang · 9 shared papers, 2018–2026 · strength 0.91
  5. Jin-Zhi Xu · 9 shared papers, 2018–2026 · strength 0.91
  6. Liang Liu · 8 shared papers, 2018–2026 · strength 0.86
  7. Zi-Hao Qi · 7 shared papers, 2018–2026 · strength 0.74
  8. Wen-Quan Wang · 9 shared papers, 2018–2020 · strength 0.74
  9. Shuo Li · 4 shared papers, 2018–2020 · strength 0.34
  10. Wenquan Wang · 1 shared paper, 2026 · strength 0.27
  11. Wei Jin · 3 shared papers, 2018–2019 · strength 0.23
  12. Shuai-Shuai Xu · 2 shared papers, 2019–2020 · strength 0.18
  13. Jin Xu · 2 shared papers, 2018–2019 · strength 0.16
  14. Quanxing Ni · 2 shared papers, 2018 · strength 0.14
  15. Wang Jiang · 1 shared paper, 2020 · strength 0.10
  16. Hao Li · 1 shared paper, 2019 · strength 0.08
  17. Shuo Li · 1 shared paper, 2019 · strength 0.08
  18. Hao Li · 1 shared paper, 2019 · strength 0.08
  19. Liang Liu · 1 shared paper, 2018 · strength 0.07
  20. Jiang Long · 1 shared paper, 2018 · strength 0.07
  21. Chen Liu · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.